|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
A myc tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a myc-tag allows one to follow the protein with an antibody against the Myc epitope. Examples are cellular localization studies by immunofluorescence or detection by Western blotting.
The peptide sequence of the myc-tag is: N-EQKLISEEDL-C (1202 Da). It can be fused to the C-terminus and the N-terminus of a protein. It is advisable not to fuse the tag directly behind the signal peptide of a secretory protein, since it can interfere with translocation into the secretory pathway.
|Rat CD70 ORF mammalian expression plasmid, C-GFPSpark tag||RG80161-ACG|
|Rat CD70 ORF mammalian expression plasmid, C-OFPSpark / RFP tag||RG80161-ACR|
|Rat CD70 ORF mammalian expression plasmid, C-Flag tag||RG80161-CF|
|Rat CD70 ORF mammalian expression plasmid, C-His tag||RG80161-CH|
|Rat CD70 ORF mammalian expression plasmid, C-Myc tag||RG80161-CM|
|Rat CD70 ORF mammalian expression plasmid, C-HA tag||RG80161-CY|
|Rat CD70 Gene cDNA clone plasmid||RG80161-G|
|Rat CD70 ORF mammalian expression plasmid, N-Flag tag||RG80161-NF|
|Rat CD70 ORF mammalian expression plasmid, N-His tag||RG80161-NH|
|Rat CD70 ORF mammalian expression plasmid, N-Myc tag||RG80161-NM|
|Rat CD70 ORF mammalian expression plasmid, N-HA tag||RG80161-NY|
|Rat CD70 natural ORF mammalian expression plasmid||RG80161-UT|
|Learn more about expression Vectors|
CD70, a member of the tumor necrosis factor superfamily, is restricted to activated T-and B-lymphocytes and mature dendritic cells. Binding of CD70 to its receptor, CD27, is important in priming, effector functions, differentiation and memory formation of T-cells as well as plasma and memory B-cell generation. Tight control of CD70 expression is required to prevent lethal immunodeficiency. By selective transcription, CD70 is largely confined to activated lymphocytes and dendritic cells (DC). As a type II transmembrane receptor, CD70 is normally expressed on a subset of B, T and NK cells, where it plays a costimulatory role in immune cell activation. Immunohistochemical analysis of CD70 expression in multiple carcinoma types. The restricted expression pattern of CD70 in normal tissues and its widespread expression in various malignancies makes it an attractive target for antibody-based therapeutics. Investigations to exploit CD70 as a cancer target have lead to the identification of potential antibody-based clinical candidates.